Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 25, 2021

Filing Date
Filed February 16, 2022
Period End
December 25, 2021
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Apr ’17Apr ’17
  2. Deal closed8-K · May ’19May ’19
  3. Deal closed8-K · Mar ’21Mar ’21
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 16, 2022. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (CRL) reported fiscal 2021 total revenue of $3.54 billiona, up from $2.92 billion in fiscal 2020, a 21.1% increase, with growth across all three reportable segments.

Operating income rose to $589.9 millionb (16.7% of revenue) from $432.7 million (14.8%), and net income attributable to common shareholders was $391.0 million, up from $364.3 million. Management attributed the results to strong demand for discovery and safety assessment services, recovery in research models from the COVID-19 disruption of the prior year, and contributions from recent acquisitions, principally Cognate BioServices and Vigene Biosciences in the Manufacturing segment. The company expanded its cell and gene therapy CDMO footprint through the 2021 acquisitions of Cognate ($879.0 million preliminary purchase price), Vigene ($323.9 million), Retrogenix and Distributed Bio, and it sold RMS Japan and its Swedish CDMO site in October 2021.

Cash provided by operating activities was $760.8 millionc, versus $546.6 million in 2020, while investing outflows were $1.44 billion, mainly for acquisitions. Total debt and finance leases stood at $2.7 billion at year-end, and the company issued $1.0 billion of 2029 and 2031 Senior Notes and extended its revolving credit facility to $3.0 billion maturing in April 2026.

The filing also flags material risks, including client demand tied to biopharmaceutical R&D funding, government NIH funding, supply constraints for large research models, contamination risk, competition, data privacy and cybersecurity, and goodwill and intangible impairment, with goodwill and other intangibles totaling $3.8 billiond. The company did not repurchase shares in 2021, had $129.1 million remaining under its repurchase authorization, and does not pay cash dividends.

Key Highlights

  1. Total revenue of $3.54 billion in fiscal 2021, up 21.1% from $2.92 billion in fiscal 2020, with DSA at $2.11 billion, RMS at $690.5 million and Manufacturing at $742.5 million.
  2. Operating income of $589.9 million, a 16.7% operating margin, compared with $432.7 million and a 14.8% margin in fiscal 2020.
  3. Net income attributable to common shareholders of $391.0 million, or $7.60 diluted EPS, versus $364.3 million and $7.20 diluted EPS in 2020.
  4. Net cash provided by operating activities of $760.8 million, up from $546.6 million, driven by higher net income and working capital improvements.
  5. Major acquisitions in 2021 included Cognate BioServices ($879.0 million preliminary purchase price) and Vigene Biosciences ($323.9 million), expanding the CDMO business; the Manufacturing segment revenue rose 44.1%.
  6. Total debt and finance leases of $2.7 billion at year-end, with $1.0 billion of 2029 and 2031 Senior Notes issued and the revolving facility increased to $3.0 billion.
  7. No shares were repurchased in fiscal 2021; $129.1 million remained under the repurchase authorization, and the company does not expect to pay cash dividends.

Financial Statements

FY2021 against FY2020

Line itemFY2021FY2020Change
Revenue$3.54B$2.92B+21.1%
SG&A Expenses$619.92M$528.93M+17.2%
Operating Income$589.86M$432.73M+36.3%
Interest Expense$73.91M$86.43M−14.5%
Net Income$390.98M$364.30M+7.3%
EPS (Basic)$7.77$7.35+5.7%
EPS (Diluted)$7.60$7.20+5.6%
Shares Outstanding (Basic)50.29M49.55M+1.5%
Shares Outstanding (Diluted)51.42M50.61M+1.6%

Frequently Asked Questions

  1. What drove the revenue increase in fiscal 2021?

    Revenue rose $616.3 million, or 21.1%, to $3.54 billion. The filing attributes the increase to demand across all segments, principally in DSA, recovery in RMS from the prior-year COVID-19 closures, the recent acquisitions mainly in Manufacturing, and favorable foreign currency effects.

  2. How did profitability change in 2021?

    Operating income increased to $589.9 million from $432.7 million, and operating margin improved to 16.7% from 14.8%. Other expense, net was $35.9 million, compared with other income of $100.0 million in 2020, mainly because of venture capital and strategic equity investment losses of $30.4 million.

  3. What acquisitions and divestitures did the company complete in 2021?

    The company acquired Cognate BioServices, Vigene Biosciences, Retrogenix, Distributed Bio and certain distributor assets. On October 12, 2021, it sold RMS Japan to The Jackson Laboratory for a preliminary price of $73.5 million and its gene therapy CDMO site in Sweden for a preliminary price of $59.6 million.

  4. How is the company financing its growth and what is its debt position?

    Total debt and finance leases were $2.7 billion at December 25, 2021. The company issued $1.0 billion of 3.75% Senior Notes due 2029 and 4.00% Senior Notes due 2031, repaid the 5.5% Senior Notes due 2026, and amended its Credit Facility to a $3.0 billion revolving facility maturing in April 2026, of which $1.16 billion was outstanding.

  5. What are the main risks highlighted for investors?

    The filing highlights risks from COVID-19, reduced or delayed biopharma and government (NIH) R&D funding, limited supply of large research models, animal contamination, competition, data privacy and cybersecurity compliance, a prior 2019 unauthorized access incident, and potential goodwill and intangible asset impairment given $3.8 billion of such balances.